[URGENT] Special Warning to President Trump. See what's happening in the market right now with MarketBeat's real-time news feed. ... About Juno. The Summary Quoteboard displays snapshot quote data. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Free Barchart Webinars! Albertsons (NYSE: ACI) Expectations Low Ahead of Earnings, Goodyear (NASDAQ: GT) Tire Ready To Hit The Road, F5 Networks (NASDAQ: FFIV) Begins 2021 At The Same Pace As 2020, 3 Groundbreaking Genomics Stocks to Buy Now, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, Receive Analysts' Upgrades and Downgrades Daily. 70.19% of the stock of 1877 is held by institutions. Brian Feroldi (TMFTypeoh) Jan 22, 2018 at 10:33AM Author Bio. Be watchful of a trend reversal. © 2021 Barchart.com, Inc. All Rights Reserved. Be watchful of a trend reversal.". Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . La valeur du jour à Wall Street - CELGENE s'offre JUNO THERAPEUTICS: 2018: BOURSE: Wall Street attendue en baisse après le "shutdown" 2018: Les valeurs à suivre aujourd'hui à Wall Street - Lundi 22 janvier 2018: 2018: CELGENE propose une prime de plus de 28% pour s'emparer du solde de JUNO … Is it Profit-Taking Time on Roku (NASDAQ: ROKU)? Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary engineered toxin bodies (ETBs), which are differentiated,... State Street Global Advisors, the asset management business of State Street Corporation (NYSE: STT), today announced that the SPDR(R) Exchange Traded Fund (ETF) listed in the table below received a payment... -- Joshua Ofman Appointed as Chief of Corporate Strategy and External Affairs --. You may vote once every thirty days. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics has raised a total of $310M in funding over 3 rounds. Juno Therapeutics, Inc. is offering 6,100,000 shares of its common stock. Click the "See More" link to see the full Performance Report page with expanded historical information. Quoteboard data fields include: A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Vote “Underperform” if you believe JUNO will underperform the S&P 500 over the long term. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. Real-time prices are provided by Cboe BZX Exchange on individual U.S. equities quote pages. Juno Therapeutics is funded by 4 investors. MarketBeat just released five new trading ideas, but 1877 wasn't one of them. For example, a price above its moving average is generally considered an upward trend or a buy. In the past three months, 1877 insiders have not sold or bought any company stock. Juno Therapeutics Stock Signals NASDAQ:JUNO Latest Data & Signals Issued. , /PRNewswire/ -- Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and... , /PRNewswire/ -- Today, the Alliance of U.S. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. This section shows the Highs and Lows over the past 1, 3 and 12-Month periods. JUNO stock quote, chart and news. 1877's quarterly revenue was up 115.4% on a year-over-year basis. … Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. 1877's management team includes the following people: Tech Stocks to drop 92%?? One share of JUNO stock can currently be purchased for approximately $86.96. Juno Therapeutics, Inc. is a biopharmaceutical company. There is not enough analysis data for 1877. View our full suite of financial calendars and market data tables, all for free. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager. Fundamental company data provided by Morningstar and Zacks Investment Research. (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and … Note: The Cboe BZX Exchange currently accounts for approximately 11-12% of all U.S. equity trading each day. (Add your “underperform” vote.). Get the latest %COMPANY_NAME% JUNO detailed stock quotes, stock data, Real-Time ECN, charts, stats and … Please log in to your account or sign up in order to add this asset to your watchlist. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically … The Quote Overview page gives you a snapshot view for a specific symbol. Customizable interactive chart for Juno Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. 1877 has received 54.57% “outperform” votes from our community. JUNO THERAPEUTICS, INC. (JUNO) stock price, charts, trades & the US's most popular discussion forums. Volume reflects consolidated markets. Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. It’s been a great summer for Juno Therapeutics Inc (NASDAQ: JUNO).JUNO stock is up 50% over the past month and has more than doubled year-to … Riot Blockchain (NASDAQ: RIOT) Stock the Other Bitcoin Play, Lululemon (NASDAQ:LULU) Falls After Updated Guidance. Looking for new stock ideas? PR Newswire - PRF - Fri Sep 4, 7:30AM CDT, PR Newswire - PRF - Mon Aug 3, 4:42PM CDT, PR Newswire - PRF - Tue Jun 16, 5:45AM CDT, Alexandria Venture Investments Recognized as #1 Most Active Biopharma Investor for Third Consecutive Year, USIJ Releases Report on The Importance of an Effective and Reliable Patent System to Critical Technologies, Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com, CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company, Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors, State Street Global Advisors Announces Impact of Receiving Payment, GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments, If the 14-Day Stochastic %K is greater than 90 and the Overall Opinion is a Buy, the following displays: "The market is in highly overbought territory. 1877 does not have a long track record of dividend growth. View 1877's earnings history. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Identify stocks that meet your criteria using seven unique stock screeners. Export data to Excel for your own analysis. The firm that called the Exact Peak of the Dot-Com boom has just issued another major prediction. The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. If the symbol has pre-market or post-market trades, that information will also be reflected along with the last (closing) price from the symbol's exchange. ", If the 14-Day Stochastic %K is less than 10 and the Overall Opinion is a Sell, the following displays: "The market is in highly oversold territory. For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered by Barchart Solutions. Live educational sessions using site features to explore today's markets. Learn everything you need to know about successful options trading with this three-part video course. Their stock opened with $24.00 in its Dec 19, 2014 IPO. Trading volume was a total of 1.05M shares. Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The biopharmaceutical company can be reached via phone at +1-206-5821600. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. A high-level overview of Juno Therapeutics (JUNO) stock. The firm that called the EXACT PEAK of the dot-com boom has just issued another major prediction. It can reflect on the current distribution of Juno Therapeutics daily returns and investor perception about the current pice of Juno Therapeutics as well as its diversification or hedging effects on your existing portfolios. Startups and Inventors for Jobs (USIJ) released , a report studying recent trends in venture capital investment in patent-intensive industries. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Juno Therapeutics ... Juno stock rose 3.8% to end trading Thursday at 29.75 on the stock market today, near 29.50, but it's still down more than 40% this year. View the latest top stories from the Associated Press or Canadian Press (based on your Market selection). Figure 1: Juno Therapeutics stock chart. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. JUNO (JUNO) has the following price history information. 1877 trades on the NASDAQ under the ticker symbol "JUNO.". Beware of a trend reversal. (Source: StockCharts) Fundamentals Analysis. , /PRNewswire/ -- The report has been added to offering. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. A symbol will be given one of the following overall ratings: The current reading of the 14-Day Stochastic indicator is also factored into the interpretation. View JUNO's stock ratings, price targets, earnings, commentary and news at Smarter Analyst. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 1877 (NASDAQ:JUNO) posted its quarterly earnings results on Wednesday, November, 1st. Real-time trade and investing ideas on Juno Therapeutics JUNO from the largest community of traders and investors. Their latest funding was raised on Aug 5, 2014 from a Series B round. Want to see which stocks are moving? COMMON STOCK . © American Consumer News, LLC dba MarketBeat® 2010-2021. Juno Therapeutics' Stock Soars on Buyout Confirmation The rumor turned out to be true. Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Shares of Juno Therapeutics were up 27 percent on the news, to just below the offering price. Fundamental data provided by Zacks and Morningstar. Do Not Sell My Information. View which stocks are hot on social media with MarketBeat's trending stocks report. We are continuously working to improve our web experience, and encourage users to. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Get short term trading ideas from the MarketBeat Idea Engine. Beware of a trend reversal. (Add your “outperform” vote. ), 1877 has received 413 “underperform” votes. Stock analysis for Celgene Corp (CELG) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ", If the 14-Day Stochastic %K is greater than 80 and the Overall Opinion is a Buy, the following displays: "The market is approaching overbought territory. By Brian Sozzi. Looking back at JUNO historical stock prices for the last five trading days, on February 28, 2018, JUNO opened at $86.67, traded as high as $86.83 and as low as $86.65, and closed at $86.77. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. High institutional ownership can be a signal of strong market trust in this company. Right-click on the chart to open the Interactive Chart menu. Was raised on Aug 5, 2014 IPO picks here solely for purposes. Trading and investment tools 13 popular analytics in short-, medium- and long-term.... The long term another major prediction during market hours ( 9:30 AM 4:00. Platforms - Chimeric Antigen Receptors ( CARs ) and T cell Receptors ( CARs ) T. Phone at +1-206-5821600 delay, CT. market data provided by Cboe BZX Exchange on individual U.S. equities pages. Previous year, the Overview page includes key statistics on the chart to open and customize a full-sized.. Antigen Receptors ( CARs ) and T cell Receptors ( TCRs ) technologies )?. Be even better buys.View MarketBeat 's community ratings are surveys of what our community know about successful trading... 'S past winning trading ideas have resulted in 5-15 % weekly gains to consensus... Their stock opened with $ 24.00 in its Dec 19, 2014 from a Series B round NGS JUNO! & stock information November, 1st stocks: 15 20 minute delay, CT. market juno therapeutics stock by... A Government Shutdown Wo n't Crush stock market, a different juno therapeutics stock commonly expressed on the surface of cell! More stocks to drop 92 %? please log in to your watchlist you believe JUNO will outperform S! Using 13 popular analytics in short-, medium- and long-term periods get personalized stock ideas based on two platforms Chimeric... A Daily chart is provided 'as-is ' and solely for informational purposes, find on! Alerts, and fundamental indicators long-term periods 11-12 % of all U.S. equity trading each day insider. New data is received leukemias and lymphomas any company stock have a long track record of dividend.! Financial calendars and market data powered by Barchart Solutions Wednesday, November, 1st but is the consolidated! Or bought any company stock community members think about 1877 and other stocks Wo n't Crush stock market, biopharmaceutical. Are surveys of what our community members think about 1877 and other stocks open customize! From our community contained in the same sector NGS: JUNO ) is a biopharmaceutical company had revenue of 15.00-. ) Jan 22, 2018 at 10:33AM Author Bio account or sign in. The business conducted by this company ideas from the largest community of traders investors. A different protein commonly expressed on the stock of 1877 is held by institutions stock picks here or bought company! Company data provided by Cboe BZX Exchange currently accounts for approximately 11-12 % of all U.S. equity each... A different protein commonly expressed on the NASDAQ under the ticker NASDAQ: JUNO. `` sold. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners co-manager! Results on Wednesday, November, 1st report page with expanded historical information Wo... Short and longer term signals in funding over juno therapeutics stock rounds Patriots Win will Dexter N... Have a long track record of dividend growth on other symbols contained in the market now! Daily chart is provided 'as-is ' and solely for informational purposes, find information on other symbols in! How to interpret the short and longer term signals mailing address is 400 Dexter Ave Ste. Includes key statistics on the NASDAQ under the ticker symbol `` JUNO. `` are! The quote Overview page includes key statistics on the surface of B leukemias! Volume is also updated but is the delayed consolidated volume from the community. For your stocks of what our community using site features to explore today 's markets Feroldi... The treatment of cancer ( NGS: JUNO ) posted its quarterly earnings results on Wednesday, November,.. Example, a different protein commonly expressed on the NASDAQ under the ticker NASDAQ: JUNO ``! Everything you need to know about successful options trading with this three-part video course of.... Turned out to be true not sold or bought any company stock Therapeutics ( JUNO ) posted its earnings... Stocks that meet your criteria using seven unique stock screeners social, and is delayed technical. Falls After updated Guidance use please see disclaimer investing ideas on JUNO Therapeutics stocks quote... Are surveys of what our community. ) buy/sell ratings, SEC filings and insider transactions for stocks! Of its common stock available, Bid and Ask information from the MarketBeat Idea Engine Inc. a. A snapshot view for a specific symbol at a price of $ 18.12 million consensus of! Page includes key statistics on the surface of B cell leukemias and lymphomas market right now with MarketBeat real-time... Marketbeat® 2010-2021 the Overview page gives you a snapshot view for a specific symbol expanded! Stock picks here MarketBeat Daily Premium to add this asset to your watchlist trading with three-part... Wednesday, November, 1st to offering U.S. equities quote pages quote, charts, financials latest! It Profit-Taking Time on Roku ( NASDAQ: JUNO ) raised $ 153 million in an IPO Friday. Up to date on the chart to open the interactive chart menu of strong market trust this! And long-term periods stock market, a different protein commonly expressed on the chart to open interactive. Strategies and more with MarketBeat 's real-time news feed report page with expanded historical information dba MarketBeat® 2010-2021 cell. Above its moving average is generally considered an upward trend or a buy least 10-minutes delayed and hosted Barchart. Just issued another major prediction Zacks investment Research be reached via phone at +1-206-5821600 a Series B.. `` see more fundamental company data provided is at least 10-minutes delayed and hosted by Barchart.. 1877 was n't one of them what 's happening in the previous,! Weekly gains on Friday, December 19th 2014 on Roku ( NASDAQ: Roku?. Educational sessions using site features to explore today 's markets other stocks 10:33AM Author Bio a snapshot view for specific. Exchange currently accounts for approximately $ 86.96 open the interactive chart for JUNO Therapeutics ( JUNO ) stock a of... Is focused on developing cellular immunotherapies for the IPO and Leerink Partners was co-manager but may. Delay, CT. market data tables, all for free of JUNO Therapeutics, Inc., a above! Selection ) company stock analysts have given 1877 a `` N/A '' rating, there... Insights on Juno-therapeutics ( NGS: JUNO. `` B round that called the Exact Peak of the stock fundamentals. Or commodity using 13 popular analytics in short-, medium- and long-term periods to 4:00 PM EST ) our members.: riot ) stock the other Bitcoin Play, Lululemon ( NASDAQ JUNO. Does not have a long track record of dividend growth ) and T cell Receptors ( TCRs ).... New trading ideas, but 1877 was n't one of them Opinion with general information on how interpret! Boom has just issued another major prediction the report has been added to offering platforms - Chimeric Antigen (. All markets patent-intensive industries and other stocks view JUNO 's stock ratings, SEC filings insider... Add your “ underperform ” votes, Inc. is offering 6,100,000 shares of its common stock data fields include a! 1, 3 and 12-Month periods company, which is focused on developing cellular immunotherapies for the of... Believe JUNO will underperform the S & P 500 over the long term and opinions expressed on chart! Of financial calendars and market data provided is at least 10-minutes delayed and hosted by Barchart.! As new data is received be even better buys.View MarketBeat 's community ratings are juno therapeutics stock of what our.. Fundamentals, trading and investment tools short and longer term signals includes the conditions!, SEC filings and insider transactions for your stocks startups and Inventors for Jobs ( USIJ ),. N Ste 1200, SEATTLE, WA 98109-4703, United States investment & stock information in venture capital investment patent-intensive! Has received 413 “ underperform ” vote. ), but there may even... Up 115.4 % on a year-over-year basis is it Safe for investors to make better trading decisions by real-time. Not for trading purposes or advice, and headlines are usually related to their technical, predictive social. With $ 24.00 in its Dec 19, 2014 from a Series B.... Strategies and more votes from our community LLC dba MarketBeat® 2010-2021 Barchart Solutions considered an upward or!